SIBN Stock Analysis: Buy, Sell, or Hold?
SIBN - SI-BONE, Inc. Common Stock
$16.08
0.25 (1.61%)
▲
5d:
+6.32%
30d:
+8.54%
90d:
+23.75%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Get Alerted When SIBN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SIBN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SIBN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SIBN is currently trading at $16.07, which is considered extended relative to its 30-day fair value range of $14.31 to $15.49.
Technical Outlook: Technically, SIBN is in a downtrend. The price is approaching resistance at $16.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SIBN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.12 (+52.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SIBN is in a downtrend. The price is approaching resistance at $16.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SIBN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.12 (+52.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$14.31 -
$15.49
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.5% below Wall St target ($24.12)
Trading Range Analysis
30-Day Trading Range
$14.31 -
$15.49
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.38
(8.6%)
Support & Resistance Levels
Support Level
$14.94
Resistance Level
$16.33
Current Trend
Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-44.83
Wall Street Target
$24.13
(+52.5%)
Revenue Growth (YoY)
11.2%
Profit Margin
-8.1%
Share & Embed Analysis
Last updated: June 23, 2026 12:05 PM ET
Data refreshes hourly during market hours. Next update: 1:05 PM
Data refreshes hourly during market hours. Next update: 1:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SIBN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Anshul Maheshwari
SELL
3318 shares
2026-04-02
Michael A Pisetsky
SELL
1335 shares
2026-04-02
Michael A Pisetsky
SELL
1799 shares
2026-04-01
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
